Treatment outcomes of 3rd treatment in a real-world metastatic castration resistant prostate cancer (mCRPC) population: Results from the Dutch CAPRI-registry

Autor: L. Lavalaye, Katja K.H. Aben, I.M. van Oort, Andre M. Bergman, D.M. Somford, J. Van Moorselaar, C.A. Uyl-de Groot, Winald R. Gerritsen, Malou C.P. Kuppen, H.M. Westgeest, A.C.M. van den Bergh, Niven Mehra, A.J.M. van den Eertwegh, Jessica Notohardjo, Jules L.L.M. Coenen, R. de Wit
Rok vydání: 2019
Předmět:
Zdroj: Annals of Oncology. 30:v338-v339
ISSN: 0923-7534
DOI: 10.1093/annonc/mdz248.022
Popis: Background Data on outcomes of a 3rd line life prolonging drug (LPD) in patients with metastatic castration resistant prostate cancer (mCRPC) is lacking. Aim of this study was to evaluate outcomes of a 3rd LPD in a real-world cohort of mCRPC patients. Methods mCRPC patients with a 3rd LPD before July 1st 2017 were retrospectively identified from the Dutch Castration-resistant Prostate Cancer Registry (CAPRI) and followed to December 31st 2017. Outcomes were overall survival (OS), treatment duration (TD) and PSA response. The association of potential risk factors with death was tested by Cox proportional-hazard models after multiple imputation of missing baseline characteristics. Results We identified 602 patients treated with a 3rd LPD. Baseline characteristics are listed in the table. Median OS was 7.8mo (IQR 4.4-14.0), median TD was 3.2mo (IQR 1.9-4.7) and PSA response (≥ 50% decline) was observed in 131 patients (22%). ECOG PS of 1 and >1 (HR 1.48, p 189 (14.8)Opioid use c153 (25.4)66 (11.0)Symptomatic c466 (77.4)50 (8.3)Metastatic site c- Bone536 (89.0)46 (7.6)- Visceral102 (16.9)260 (43.1)- Lymphnode263 (43.7)208 (43.5)Hemoglobin (mmol/l) a7.2 ± 1.154 (9.0)Platelets (109/L) b253 (199.0-320.7)62 (10.3)Prostate-specific antigen (ug/l) b170 (60.9-470.5)37 (6.1)Alkaline phosphatase (U/l) b153 (90.5-301.0)61 (10.1)Lactate dehydrogenase (U/l) b261 (207.5-383.0)144 (23.9)3rd line LPD treatment c- Abiraterone acetate137 (22.8)0- Enzalutamide129 (21.4)0- Docetaxel45 (7.5)0- Cabazitaxel213 (35.4)0- Radium-223-chloride78 (13.0)0Note: Data are defined as amean ± SD, bmedian (IQR) or cnumber of patients (%). Abbreviations: CRPC; Castration-resistant prostate Cancer, ECOG PS;Eastern Cooperative Oncology Group Performance Score. Conclusions Our results show that the efficacy of a 3rd LPD in mCRPC patients was limited compared to pivotal trials of 1st and 2nd line. We used a simple prognostic model to identify mCRPC patients that can benefit from a 3rd LPD. Clinical trial identification NL3440 (NTR3591). Legal entity responsible for the study Institute for Medical Technology Assessment, Erasmus University Rotterdam. Funding Sanofi-Aventis Netherlands B.V., Janssen-Cilag B.V., Astellas Pharma B.V., Bayer B.V. Disclosure M.C.P. Kuppen: Travel / Accommodation / Expenses: Ipsen. H.M. Westgeest: Travel / Accommodation / Expenses: Ipsen; Honoraria (self): Roche. A.J.M. van den Eertwegh: Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Sanofi; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: MSD Oncology; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy: Ipsen; Honoraria (institution), Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Amgen; Advisory / Consultancy: Novartis; Advisory / Consultancy: Merck. J. Van Moorselaar: Honoraria (institution), Advisory / Consultancy: Amgen; Honoraria (institution), Advisory / Consultancy: Astellas; Honoraria (institution), Advisory / Consultancy: AstraZeneca; Honoraria (institution), Advisory / Consultancy: Bayer; Honoraria (institution), Advisory / Consultancy: Janssen; Honoraria (institution), Advisory / Consultancy: Sanofi-Genzyme. N. Mehra: Research grant / Funding (institution): Astellas; Honoraria (self), Research grant / Funding (institution): Janssen; Research grant / Funding (institution): Pfizer; Honoraria (self), Research grant / Funding (institution): Sanofi; Honoraria (self), Research grant / Funding (institution): Roche; Honoraria (self): Merck; Honoraria (self): Bayer; Honoraria (self): BMS; Honoraria (self): MSD. J.L. Coenen: Advisory / Consultancy: Sanofi. I. van Oort: Advisory / Consultancy, Research grant / Funding (institution): Astellas; Advisory / Consultancy, Research grant / Funding (institution): Janssen; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Roche; Advisory / Consultancy: Mdx Health; Advisory / Consultancy: Astellas. D.M. Somford: Research grant / Funding (institution): Astellas. R. de Wit: Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Honoraria (institution), Advisory / Consultancy: Merck; Honoraria (institution), Advisory / Consultancy: SharpD Advisory / Consultancy: Roche/ Genentech; Advisory / Consultancy: Janssen; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Clivis; Travel / Accommodation / Expenses: Lilly. A.M. Bergman: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Sanofi; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Astellas; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer; Speaker Bureau / Expert testimony: Janssen. C. Uyl-de Groot: Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Astellas; Research grant / Funding (institution): Celgene; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Janssen-Cilag; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Genzyme; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Glycostem Therapeutics; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Merck. W.R. Gerritsen: Advisory / Consultancy, Speaker Bureau / Expert testimony: Astellas; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bayer; Speaker Bureau / Expert testimony: Bavarian Nordic; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Speaker Bureau / Expert testimony: MSD; Advisory / Consultancy, Speaker Bureau / Expert testimony: Janssen-Cilag; Advisory / Consultancy: Amgen; Advisory / Consultancy: Merck; Advisory / Consultancy: Morphosys; Advisory / Consultancy: Sanofi; Advisory / Consultancy, Ad hoc Consultancy: Aglaia Biomedical Ventures; Advisory / Consultancy, Ad hoc Consultancy: Psioxus Therapeutics; Advisory / Consultancy: Curvevac; Advisory / Consultancy: Dendreon. All other authors have declared no conflicts of interest.
Databáze: OpenAIRE
Externí odkaz: